Trials / Completed
CompletedNCT02766517
Biomarker Study in Participants With Migraine
LY2951742 Biomarker Study in Patients With Migraine
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a study of participants with a diagnosis of migraine who completed another clinical trial NCT02163993. The participants received either LY2951742 or placebo. This study NCT02766517 will evaluate how certain biomarkers may be related to the participant's response in study NCT02163993. The study will last about five days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capsaicin | Administered topically |
Timeline
- Start date
- 2016-09-28
- Primary completion
- 2017-01-01
- Completion
- 2017-01-01
- First posted
- 2016-05-09
- Last updated
- 2019-04-09
- Results posted
- 2019-02-26
Locations
14 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02766517. Inclusion in this directory is not an endorsement.